| Group 1 (n = 88) | Group 2 (n = 89) | Group 3 (n = 89) | p-value |
AGE | 65.5 (±7.93) | 66.8 (±6.86) | 68.3 (±7.74) | 0.042 |
ASA | 2 | 2 | 2 | ns |
BMI (kg/m2) | 26.2 (±3.54) | 26.6 (±3.78) | 26.1 (±4.16) | ns |
PSA (ng/ml) | 4.79 (±4.24) | 6.01 (±6.29) | 5.08 (±4.06) | ns |
Qmax (ml/s) | 8.51 (±4.25) | 8.55 (±3.77) | 8.99 (±4.27) | ns |
PVR 9 (ml) | 144 (±142) | 120 (±112) | 127 (±124) | ns |
IPSS | 19.1 (±7.04) | 17.9 (±6.36) | 17.1 (±6.68) | ns |
Prostate volume (ml) | 75.7 (±34.1) | 85.2 (±44.1) | 79.5 (±45.1) | ns |
Patients with prostate volume > 90 (ml) | 31 (37%) | 29 (36%) | 28 (33%) | ns |
Operation time (minutes) | 77.0 (±30.8) | 60.4 (±24.5) | 55.4 (±24.0) | <0.001 |
Resection tissue weight (g) | 44.2 (±33.6) | 50.4 (±33.8) | 42.4 (±27.9) | ns |
Delivered energy (kj) | 95.2 (±49.8) | 84.0 (±38.7) | 77.9 (±45.4) | 0.041 |
Indwelling catheter before surgery | 5 (5.7%) | 8 (9.9%) | 9 (10%) | ns |
Antiplatelet therapy | 7 (8%) | 15 (17%) | 17 (19%) | ns |
Day-case success | 62 (70%) | 75 (84%) | 77 (87%) | 0.014 |